Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) Net Margin (2022 - 2025)

TriSalus Life Sciences' Net Margin history spans 4 years, with the latest figure at 73.86% for Q4 2025.

  • For Q4 2025, Net Margin rose 5798.0% year-over-year to 73.86%; the TTM value through Dec 2025 reached 157.51%, down 4459.0%, while the annual FY2025 figure was 154.35%, 4143.0% down from the prior year.
  • Net Margin reached 73.86% in Q4 2025 per TLSIW's latest filing, up from 356.86% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 36.26% in Q3 2023 to a low of 786.45% in Q4 2022.
  • Average Net Margin over 4 years is 244.0%, with a median of 169.07% recorded in 2022.
  • Peak YoY movement for Net Margin: soared 50510bps in 2024, then crashed -31329bps in 2025.
  • A 4-year view of Net Margin shows it stood at 786.45% in 2022, then rose by 19bps to 636.93% in 2023, then skyrocketed by 79bps to 131.84% in 2024, then soared by 44bps to 73.86% in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Net Margin are 73.86% (Q4 2025), 356.86% (Q3 2025), and 80.28% (Q2 2025).